Factor XIII Mutation (V34L)

Service Description

Factor XIII, also known as fibrin stabilizing factor, is a protein that plays a role in blood clotting. This test uses PCR-Hybridization to detect the V34L mutation which is a genetic variation in the Factor XIII gene that has been associated with an increased risk of bleeding disorders. The V34L mutation reduces the activity of Factor XIII, which can lead to an increased tendency for bleeding and delayed wound healing. Individuals who carry the V34L mutation have a higher risk of developing bleeding disorders, such as congenital Factor XIII deficiency. The V34L mutation is inherited in an autosomal recessive pattern, which means that an affected person needs to inherit two copies of the mutated gene (one from each parent) to develop the condition. Testing for the V34L mutation may be recommended in individuals with a personal or family history of bleeding disorders or unexplained bleeding symptoms. Individuals who test positive for the mutation may be advised to take steps to reduce their risk of bleeding, such as avoiding certain medications or activities that increase the risk of bleeding. In some cases, individuals with the V34L mutation may require treatment with Factor XIII replacement therapy to prevent bleeding or promote wound healing. Sample: BLOOD Results:2 weeks Phlebotomy fee: £15 (included in price)